ZymoGenetics Presents PEG-Interferon Lambda Data

ZymoGenetics discussed data from a Phase Ia clinical trial with PEG-Interferon lambda.

The primary objectives of the randomized, placebo-controlled, dose-escalation study were to characterize the safety, tolerability and pharmacokinetics of a single dose of the drug administered subcutaneously.

Twenty subjects were treated with PEG-Interferon lambda at doses of up to 7.5 mcg/kg or placebo. The drug was well tolerated at doses of up to 5 mcg/kg, ZymoGenetics said.